Cataflam D contains diclofenac potassium, an NSAID that is commonly used for short-term and acute relief. The core therapeutic aim of this medication plays a role in managing symptoms related to inflammatory or irritative states and physical discomfort.

The medication is generally applied in addressing symptoms that interfere with daily functioning across several therapeutic domains. The medication is used to assist with easing symptoms related to mild-to-moderate physical discomfort. It is applied in addressing symptom clusters related to conditions characterized by periods of heightened symptoms, such as painful menstrual periods, the acute manifestations of migraine, and chronic conditions like osteoarthritis and rheumatoid arthritis.

This supportive relief assists with maintaining functional stability during episodes of heightened discomfort. The drug’s purpose is often summarized as:

“It may help patients cope more steadily with symptom fluctuations.”

In clinical scenarios where short-term symptomatic assistance is needed, Cataflam D generally contributes to easing the overall symptom load, including symptoms of inflammation, swelling, stiffness, and joint pain.

Quick Fact: Support for Acute Pain
Cataflam D is commonly used to help with symptoms associated with acute or episodic changes, and may assist in offering supportive relief when symptoms become more disruptive during flare-ups.

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility and Contraindications

Regulatory agencies define specific population groups who are eligible, restricted, or prohibited from using Cataflam D (Diclofenac Potassium). Use is generally established for adults (18 years and older).

Category	Eligibility Status (Regulatory Wording)
Absolute Contraindications	Prohibited for patients with a known hypersensitivity to diclofenac or other NSAIDs (e.g., aspirin-induced asthma or urticaria), and for pain management following Coronary Artery Bypass Graft (CABG) surgery or when active gastrointestinal ulceration/bleeding is present.
Severe Organ Function	Contraindicated in cases of severe hepatic failure, severe renal failure, or severe cardiac failure (NYHA Class II-IV for high-dose/long-term use).
Pregnancy	Contraindicated in the last trimester of pregnancy (from 30 weeks gestation). Use is limited/avoided between 20 and 30 weeks gestation.
Pediatric Use	Not recommended for children and adolescents under 14 years of age in some regions, and safety/effectiveness have not been established for this formulation in U.S. pediatric patients.
Conditional Use	Caution is advised for older adults (who have a higher risk of adverse events), breastfeeding women (not recommended), and patients with mild-to-moderate renal or hepatic impairment or uncontrolled hypertension.

These official statements delineate the specific clinical states, age groups, and pre-existing conditions that strictly determine a patient's eligibility to use this medicine.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Diclofenac Potassium through pharmacokinetic modifications and pharmacodynamic reinforcements.

Documented Interaction Patterns

Interaction Type	Interacting Substances/Context	Official Outcome or Restriction
Formal Contraindication	Peri-operative pain treatment in the setting of Coronary Artery Bypass Graft (CABG) surgery	Prohibited for use due to increased cardiovascular thrombotic risk.
PK Exposure Increase	CYP2C9 Inhibitors (e.g., Voriconazole)	Significantly increases the plasma concentration of diclofenac.
PK Clearance Inhibition	Methotrexate	Inhibits renal clearance, resulting in increased methotrexate levels and potential toxicity.
PD Bleeding Risk	Anticoagulants, Anti-platelet Agents, SSRIs, Oral Corticosteroids	Increases the risk of serious bleeding or gastrointestinal ulceration.
PD Renal/BP Effects	ACE Inhibitors, ARBs, Diuretics	May diminish the antihypertensive effect and concurrently raise the risk of renal damage.

Substance and Timing Constraints

Co-administration with other systemic NSAIDs is officially discouraged due to the potential for additive adverse gastrointestinal effects. The label specifies that Alcohol consumption increases the risk of serious GI bleeding. Furthermore, administration with food causes a reduction in the peak plasma concentration and delays absorption. For Methotrexate, caution is recommended when Diclofenac Potassium is administered less than 24 hours before treatment. Elderly patients are officially noted to face more serious consequences from adverse reactions involving these interactions.

Core Mechanism: Inhibiting Prostaglandin Synthesis

The action of Diclofenac Potassium involves intervention through enzyme inhibition within the chemical pathways that mediate nociception and vascular physiological processes. The drug's primary function is to act as a competitive inhibitor of the Cyclooxygenase (COX) enzymes, targeting both COX-1 and COX-2. By blocking these enzymes, the compound rapidly suppresses the biosynthesis of Prostaglandin E2 ( PGE2), a key chemical mediator involved in inflammatory and pyretic processes. This immediate molecular suppression is related to the immediate-release Potassium salt formulation, which results in rapid achievement of the concentration necessary for enzyme inhibition.

Modulating Pain Signaling and Thermoregulation

The reduction in PGE2 concentration leads to a dual physiological effect. Peripherally, it prevents the sensitization of nociceptors (pain nerves), which increases the activation threshold of peripheral nociceptors at the site of tissue damage. Centrally, the suppressed PGE2 levels in the hypothalamus allow the thermoregulatory setpoint to be reversed. The combined action results in the concurrent modulation of inflammatory mediator signaling and the adjustment of temperature regulation.

Mechanistic Constraints

The mechanism is focused solely on mediator signaling and does not involve modification of the underlying cellular or pathological progression. Furthermore, the mechanism demonstrates reduced activity in physiological pathways that are not significantly mediated by Prostaglandin activity.

The official use of Cataflam D, a 50 mg immediate-release tablet of Diclofenac Potassium, is governed by established guidelines to ensure appropriate administration. It is a medicine for oral administration only.

Official Administration Guidelines

Feature	Guideline
Route of Administration	Oral. The tablet is taken by mouth.
Dosing Principle	Use the lowest effective dose for the shortest duration consistent with the individual patient's treatment goals.
Dosing Schedule	The total daily dose is administered in divided doses (multiple times per day). For example, 50 mg doses are often taken three or four times daily for arthritis or acute pain.
Maximum Daily Dose	The dosage regimens for the immediate-release tablet support a daily maximum of 150 mg to 200 mg in divided doses, depending on the indication.

Proper Intake and Handling

To maintain the characteristics of the immediate-release formulation, the tablet must be swallowed whole and not crushed, broken, or chewed. While food does not affect the total absorption, taking the medicine with a meal may delay the onset of action.

Population-Specific Use

For older adults, caution is generally indicated, recommending the lowest effective dose for the shortest time. The safety and effectiveness of the immediate-release tablet have not been established in pediatric patients.

Research Evidence: Overview of Studies for Cataflam D

This overview outlines the type of research available for Diclofenac Potassium (Cataflam D) and describes the focus of these studies. It focuses strictly on the evidence landscape—the types of trials, the outcomes researchers chose to measure, and the limitations noted—without interpreting results, making claims of effectiveness, or offering any clinical advice. Research provides context but not individual predictions; study results reflect the specific conditions under which they were conducted.

---

Evidence for Use in Acute Pain and Primary Dysmenorrhea

The research exploring short-term symptom changes for Cataflam D primarily focuses on its use in managing outcomes related to physical discomfort, which includes mild-to-moderate pain, pain following minor procedures, and studies assessing symptoms in women experiencing painful menstrual periods (Primary Dysmenorrhea).

The research related to this area largely comes from Short-Term Randomized Controlled Trials (RCTs) and aggregated data summarized in Systematic Reviews and Meta-analyses. These studies monitored specific measurements of pain intensity and how quickly participants reported a change in their symptom perception. In trials where the immediate-release formulation was studied for short-term symptom management, research describes patterns related to pain measurements over the first few hours after administration.

Evidence for Use in Chronic Condition Flare-ups

This area of research explores short-term symptom changes when Cataflam D is evaluated for use during acute episodes in conditions characterized by fluctuating or episodic manifestations like Osteoarthritis (OA) and Rheumatoid Arthritis (RA). Research examined the immediate-release formulation against standard or delayed-release Diclofenac forms in Comparative Controlled Trials. These studies monitored outcomes reflecting daily functioning or activity level and tracked functional rating scores during periods of heightened symptom activity.

Research Gaps and Areas of Uncertainty

The primary research limitation is that the follow-up durations were limited in many key trials. This means that while research provides insight into short-term changes, there is limited information for long-term outcomes regarding this specific formulation. Additionally, evidence quality varies across studies, and data for certain subgroups (such as children or patients with complex comorbidities) remain insufficient. Finally, comparative evidence is generally robust for acute symptom management, but comparative evidence is lacking for the sustained measures of effect of the immediate-release form versus standard formulations over intermediate periods.

Key Studies & References

1. Diclofenac Potassium Tablets, USP 25 mg and 50 mg - DailyMed (NIH)

Common questions about Cataflam D (FAQ)

---

Q: How quickly does Cataflam D start working?

The medicine’s formulation is associated with rapid absorption, which is intended for acute symptom management. In some studies of fasting subjects, measurable levels of the active ingredient were observed within 10 minutes of taking the dose. Peak concentration in the blood is typically reached around one hour in fasting subjects, a characteristic consistent with acute symptom management.

---

Q: How long do the effects of Cataflam D last?

The terminal half-life of the active ingredient, diclofenac, is approximately 1.9 hours as reported in regulatory documents. This measurement describes the time it takes for half of the drug to be eliminated from the body, which is consistent with its use for short-term symptom management.

---

Q: Is it common to feel stomach upset after taking Cataflam D?

Yes, official safety documents classify several gastrointestinal effects as common adverse reactions, occurring in 1% to 10% of patients. These effects, which can be perceived as stomach upset, include nausea, diarrhea, and abdominal pain.

---

Q: Can Cataflam D affect fertility?

Regulatory-sourced information indicates that anti-inflammatory medicines in this class may temporarily affect the process of ovulation in women. This temporary effect is a safety consideration that could potentially make conception more difficult.

---

Q: Does taking Cataflam D with milk help reduce stomach irritation?

There is no specific regulatory instruction about milk. Official documents state that taking the medicine with food can delay the onset of action and reduce the peak concentration of the drug. Taking the medicine with a meal or dairy is associated with a slower onset of action.

---

Q: Can Cataflam D cause difficulty sleeping?

Difficulty sleeping (insomnia) is not listed as a common side effect in regulatory documents. The related adverse reaction of somnolence (drowsiness) is classified separately as a rare event.

---

Q: Can Cataflam D affect alertness or driving ability?

Official safety documents list dizziness and vertigo as common side effects. Because these effects can impact reaction time and alertness, official documents describe a recommendation for caution with activities requiring full attention, such as driving or operating machinery.

---

Q: What does 'use with caution' generally mean in drug labels for Cataflam D?

The term is used by regulatory bodies to identify patient groups who have a higher potential for adverse effects, such as older adults or those with certain pre-existing conditions. The term is used to highlight that heightened vigilance or dose adjustment is a regulatory principle when used in these specific patient groups.

---

Q: Why is Cataflam D sometimes prescribed for dental pain?

The medicine’s rapid-action formulation is associated with a quick onset of action, tied to its anti-inflammatory mechanism. This characteristic is considered beneficial for managing acute, immediate discomfort such as pain following a dental procedure.

---

Q: Is it okay to have coffee while taking Cataflam D?

Official drug labels do not list a specific interaction between the active ingredient (diclofenac) and caffeine. However, official safety information advises general caution regarding consumption habits while taking medication.

---

Q: Can I take Cataflam D if I also take a multivitamin?

There is no specific formal interaction listed for a generic multivitamin. Official safety documentation consistently recommends that patients inform their healthcare provider about all vitamins, supplements, and other medicines they use.

---

Q: Is Cataflam D known to interact with herbal supplements?

Official sources advise caution regarding herbal remedies and supplements. This is because there is often insufficient data to confirm safety, which is the regulatory basis for the caution.

---

Q: Can Cataflam D be used by breastfeeding mothers?

Official documentation advises caution and states that use is generally not recommended for breastfeeding women. Regulatory studies indicate the medicine passes into breast milk in small amounts.

---

Q: Is it normal to feel dizzy or drowsy after taking Cataflam D?

Dizziness is listed as a common adverse reaction, with a frequency of 1% to 10% in official documents. Drowsiness (somnolence) is classified separately as a rare event.

---

Q: Is Cataflam D studied for use in chronic conditions?

Regulatory documents state that this medicine is indicated for the relief of the signs and symptoms of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis, which reflects the conditions under which the medicine has received official indications.

---

Q: Has there been recent research on the long-term use of Cataflam D?

Regulatory evidence reviews highlight that while studies provide clear insight into short-term changes, there is limited available research information regarding long-term outcomes for this specific immediate-release formulation.

---

Q: What is the significance of the research evidence mentioned for Cataflam D?

The research evidence, which includes short-term trials and systematic reviews, is part of the evidence used by regulatory bodies to support the drug's official indications and properties in managing acute pain symptoms.

---

Q: Does Cataflam D show up on drug tests?

No, the active ingredient, diclofenac, is a nonsteroidal anti-inflammatory drug (NSAID) and is not classified as a controlled substance. Standard drug tests do not screen for this type of medication.

---

Q: Can Cataflam D be used for muscle aches and strains?

The medicine is officially indicated for the relief of mild to moderate pain. This is the broad regulatory category that covers the management of symptoms associated with common discomforts such as muscle aches and strains.

---

Q: What is the purpose of the 'Excipients' listed in the drug information?

Excipients, or inactive ingredients, are non-medicinal substances included in the final product to help with the tablet's manufacture, stability, and proper absorption of the active ingredient. They do not contribute directly to the drug's therapeutic effects.

---

Q: Can Cataflam D interact with common heartburn medications?

Official labels do not list a general interaction with all common heartburn medications. However, caution is advised for certain antacids, particularly those containing aluminum, in patients with pre-existing kidney conditions due to potential absorption changes.

Storage and Disposal of Cataflam D (Diclofenac Potassium)

Cataflam D tablets must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container and protected from both light and moisture. Exposure to excessive heat or freezing is prohibited.

Required Conditions

Condition	Requirement
Temperature	Controlled Room Temperature (20 C to 25 C)
Protection	Protect from light, moisture, and freezing.
Safety	Keep out of the sight and reach of children and pets.

For disposal, unused or expired Cataflam D must not be flushed down the toilet or disposed of in the drain. Disposal should follow official guidance, such as using an authorized medicine take-back program. If a take-back program is not available, the medicine should be mixed with an unappealing substance, sealed in a bag, and discarded in the household trash.